Thromb Haemost 1998; 79(04): 824-831
DOI: 10.1055/s-0037-1615072
Rapid Communication
Schattauer GmbH

Fibrinogen Coating Density Affects the Conformation of Immobilized Fibrinogen: Implications for Platelet Adhesion and Spreading

Keith A. Moskowitz
1   From the Division of Hematology, Department of Medicine, The Mount Sinai School of Medicine, New York, NY, USA
,
Bohdan Kudryk
2   From The New York Blood Center, New York, NY, USA
,
Barry S. Coller
1   From the Division of Hematology, Department of Medicine, The Mount Sinai School of Medicine, New York, NY, USA
› Institutsangaben
Supported by grant 19278 from the National Heart, Lung and Blood Institute
Weitere Informationen

Publikationsverlauf

Received 07. August 1997

Accepted after revision 26. November 1997

Publikationsdatum:
07. Dezember 2017 (online)

Summary

Adhesion of platelets to immobilized fibrinogen appears to play an important role in a variety of physiologic and pathologic phenomena. We previously observed that the fibrinogen concentration used to coat polystyrene wells affected the morphology and distribution of GP IIb/ IIIa receptors on the surface of platelets adherent to the fibrinogen. One possible explanation for these differences is that fibrinogen immobilized at high density adopts a different conformation than fibrinogen immobilized at low density. To address this possibility, we studied the binding of a panel of anti-fibrinogen monoclonal antibodies (mAbs) to fibrinogen immobilized at different coating densities. Three different patterns of binding were observed: 1) a linear increase in binding to wells coated with 1-10 μg/ml fibrinogen, followed by a lesser increase or plateau at higher fibrinogen concentrations (mAbs Fd4-4E1, Fd4-7B3, 1D4, 4-2); 2) minimal reactivity at all fibrinogen concentrations (mAbs GC4-1A12, 2C34); 3) a biphasic response, with a linear increase up to 10 μg/ml fibrinogen and then a significant decline in binding at higher fibrinogen concentrations (mAbs 311, 31A9, FPA 19/7, 9C3, 1C5-A5/2, 44-3). The patterns of mAb binding to fibrinogen immobilized from plasma were similar. Most mAbs that demonstrated a biphasic response bound poorly or not at all to soluble fibrinogen, while mAbs that demonstrated a linear/plateau response were able to bind soluble fibrinogen. At equal surface densities, mAbs that bound biphasically, particularly mAb 1C5-A5/2, were more reactive to urea-denatured than native fibrinogen. mAbs 1C5-A5/2 and 44-3 are specific for γ 1-78 and 95-265, respectively, suggesting that the fibrinogen γ-chain may be sensitive to changes in conformation induced by immobilization. In summary, these data suggest that fibrinogen immobilized at 1-10 μg/ml adopts a conformation unlike soluble fibrinogen, while fibrinogen immobilized at >30 μg/ml adopts a more solution-like conformation. These differences in fibrinogen conformation may partially account for the ability of platelets to bind to immobilized fibrinogen without the addition of agonist, as well as the differences in spreading and GPIIb/IIIa distribution on platelets adherent to high- versus low-density immobilized fibrinogen.

 
  • References

  • 1 Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
  • 2 Bini A, Kudryk BJ. Fibrinogen and fibrin in the arterial wall. Thromb Res 1994; 75: 337-41.
  • 3 Bini A, Kudryk BJ. Fibrinogen in human atherosclerosis. Ann NY Acad Sci 1995; 748: 461-73.
  • 4 Smith EB. Fibrinogen and fibrin degradation products in atherosclerotic plaques. Thromb Res 1994; 75: 329-35.
  • 5 Hatton MWCS, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135: 499-508.
  • 6 Salzman EW, Lindon J, McManama G, Ware JA. Role of fibrinogen in activation of platelets by artificial surfaces. Ann NY Acad Sci 1987; 516: 184-95.
  • 7 Ziats NP, Pankowsky DA, Tierney BP, Ratnoff OD, Anderson JM. Adsorption of Hageman factor and other human plasma proteins to biomedical polymers. J Lab Clin Med 1990; 116: 687-96.
  • 8 Chinn JA, Horbett TA, Ratner BD. Baboon fibrinogen adsorption and platelet adhesion to polymeric surfaces. Thromb Haemost 1991; 65: 608-17.
  • 9 Nagai H, Handa M, Kawai Y, Watanabe K, Ikeda Y. Evidence that plasma fibrinogen and platelet membrane GPIIb-IIIa are involved in the adhesion of platelets to an artificial surface exposed to plasma. Thromb Res 1993; 71: 467-77.
  • 10 Batllu AL, Laurent A, Lu H, Elalami I, Jacob P, Mundler O, Merland JJ, Lautier A, Soria J, Soria C. Fibrinogen binding and platelet retention: relationship with the thrombogenicity of catheters. J Biomed Mater Res 1996; 30: 101-8.
  • 11 Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: Defective platelet-fibrinogen interaction in thrombasthenia. Blood 1980; 55: 169-78.
  • 12 Park K, Mosher DF, Cooper SL. Acute surface-induced thrombosis in the canine ex vivo model: Importance of protein composition of the initial platelet monolayer and platelet activation. J Biomed Mater Res 1986; 20: 589-612.
  • 13 Coller BS, Kutok JL, Scudder LE, Galanakis DK, West SM, Rudomen GS, Springer KT. Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest 1993; 92: 2796-806.
  • 14 Salzman EW, Merrill EW, Kent KG. Interaction of blood with artificial surfaces. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. J.B. Lipincott Company; Philadelphia, PA: 1994. pp 1469-85.
  • 15 Savage BJ, Ruggeri ZM. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on non-activated platelets. J Biol Chem 1991; 266: 11227-33.
  • 16 Kieffer N, Fitzgerald LA, Wolf D, Cheresh DA, Phillips DR. Adhesive properties of the β3 integrins: comparison of GPIIb-IIIa and the vitronectin receptor expressed in human melanoma cells. J Cell Biol 1991; 113: 451-61.
  • 17 Peerschke EIB. The platelet fibrinogen receptor. Semin Hematol 1985; 22: 241-59.
  • 18 Lindon JN, McManama G, Kushner L, Merrill EW, Salzman EW. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces?. Blood 1986; 68: 255-62.
  • 19 Shiba E, Lindon JN, Kushner L, Matsueda GR, Hawiger J, Kloczewiak M, Kudryk B, Salzman EW. Antibody-detectable changes of fibrinogen adsorption affecting platelet activation on polymer surfaces. Am J Physiol 1991; 260: C965-74.
  • 20 Coller BS, Springer KT, Beer JH, Mohandas N, Scudder LE, Norton KJ, West SM. Thromboerythrocytes: in vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992; 89: 546-55.
  • 21 Galanakis DK. Plasma cryoprecipitation studies: major increases in fibrinogen yield by albumin enrichment of plasma. Thromb Res 1995; 303-13.
  • 22 Cierniewski CS, Budzynski AZ. Involvement of the α-chain in fibrin clot formation: effect of monoclonal antibodies. Biochemistry 1992; 31: 4248-53.
  • 23 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
  • 24 Green NM. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J 1965; 94: 23c-4c.
  • 25 Procyk R, Bishop PD, Kudryk B. Recombinant human factor XIIIa-subunit association. Thromb Res 1993; 71: 127-38.
  • 26 Procyk R, Kudryk B, Callender S, Blombäck B. Accessibility of epitopes on fibrin clots and fibrinogen gels. Blood 1991; 77: 1469-75.
  • 27 Bini A, Mesa-Tejada R, Fenoglio JJ, Kudryk B, Kaplan KL. Immunohisto-chemical characterization of fibrin(ogen)-related antigen in human tissues using monoclonal antibodies. Lab Invest 1989; 60: 814-21.
  • 28 Budzynski AZ. Fibrinogen and fibrin: biochemistry and pathophysiology. CRC Critical Reviews in Oncology and Hematology 1986; 6: 97-146.
  • 29 Kudryk B, Rohoza A, Ahadi M, Gidlund M, Harfenist EJ. Antibodies specific for neoantigens expressed on chains or degradation products of fibrin(ogen). In: Fibrinogen 3 – Biochemistry, Biological Functions, Gene Regulation, and Expression. Mossesson MW, Amrani DL, Siebenlist KR, DiOrio JP. eds. Elsevier Science Publishers, BV; Amsterdam,: 1988. pp 129-32.
  • 30 Cierniewski CS, Kloczewiak M, Budzynski AZ. Expression of primary polymerization sites in the D domain of human fibrinogen depends on intact conformation. J Biol Chem 1986; 261: 9116-21.
  • 31 Chinn JA, Posso SE, Horbett TA, Ratner BD. Postadsorptive transitions in fibrinogen adsorbed to biomer: changes in baboon platelet adhesion, antibody binding, and sodium dodecyl sulfate elutability. J Biomed Mater Res 1991; 25: 535-55.
  • 32 Horbett TA, Lew KR. Residence time effects on monoclonal antibody binding to adsorbed fibrinogen. J Biomater Sci Polymer Ed 1994; 6: 15-33.
  • 33 Rapoza RJ, Horbett TA. Changes in the SDS elutability of fibrinogen adsorbed from plasma to polymers. J Biomater Sci Polymer Ed 1989; 1: 99-110.
  • 34 Retzinger GS, Cook BC, Deanglis AP. The binding of fibrinogen to surfaces and the identification of two distinct surface-bound species of the protein. J Colloid Interface Sci 1994; 168: 514-21.
  • 35 Cook BC, Retzinger GA. Lipid microenvironment influences the processivity of adsorbed fibrin(ogen): enzymatic processing and adhesivity of bound protein. J Colloid Interface Sci 1994; 162: 171-81.
  • 36 Retzinger GS. Adsorption and coagulability of fibrinogen on atheromatous lipid surfaces. Arterioscler Thromb Vasc Biol 1995; 15: 786-92.
  • 37 Hantgan RR, Francis CW, Marder VJ. Fibrinogen structure and physiology. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. J.B. Lipincott Company; Philadelphia, PA: 1994. pp 277-300.
  • 38 Moskowitz KA, Boeger C, Scudder LE, Patel D, Vaananen H, Eisinger J, Coller BS. Platelets spread differently on low density versus high density fibrinogen as judged by their shape change and ability to bind soluble fibrinogen. Blood 1996; 88: 34a.
  • 39 Schielen WJG, Voskuilen M, Tesser GI, Niewenhuizen W. The sequence Aα-(148-160) in fibrin, but not fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 8951-4.
  • 40 Zamarron C, Ginsberg MH, Plow EF. Monoclonal antibodies specific for a conformationally altered state of fibrinogen. Thromb Haemost 1990; 64: 41-6.
  • 41 Parise LV, Steiner B, Nannizzi L, Criss AB, Phillips DR. Evidence for novel binding sites on the platelet glycoprotein IIb and IIIa subunits and immobilized fibrinogen. Biochem J 1993; 289: 445-51.
  • 42 Peerschke EIB, Galanakis DK. Platelet adhesion to late fibrinogen degradation products. Blood Coag Fibrinol 1996; 7: 353-60.
  • 43 Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
  • 44 Zamarron C, Ginsberg MH, Plow EF. A receptor-induced binding site in fibrinogen elicited by its interaction with platelet membrane glycoprotein IIb-IIIa. J Biol Chem 1991; 266: 16193-9.
  • 45 Ugarova TP, Budzynski AZ, Shattil SJ, Ruggeri ZM, Ginsberg MH, Plow EF. Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa. J Biol Chem 1993; 268: 21080-87.
  • 46 Thorsen LI, Hessel B, Brosstad F, Gogstad G, Solum NO. The N-DSK γ-chain binds to immunoprecipitated GP IIb-IIIa. Thromb Res 1987; 47: 315-21.
  • 47 Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxy-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 1993; 268: 13577-85.
  • 48 Gorkun OV, Veklich YI, Medved LV, Henschen AH, Weisel JW. Role of the αC domains of fibrin in clot formation. Biochemistry 1994; 33: 6986-97.
  • 49 Okada M, Blombäck B, Chang MD, Horwitz B. Fibronectin and fibrin gel structure. J Biol Chem 1985; 260: 1811-20.
  • 50 Bale MD, Westrick LG, Mosher DF. Incorporation of thrombospondin into fibrin clots. J Biol Chem 1985; 260: 7502-8.
  • 51 Loscalzo J, Inbal A, Handin RI. von Willebrand factor facilitates platelet incorporation in polymerizing fibrin. J Clin Invest 1986; 78: 1112-19.
  • 52 Parker RI, Gralnick HR. Fibrin monomer induces binding of endogenous platelet von Willebrand factor to the glycocalicin portion of platelet glycoprotein Ib. Blood 1987; 70: 1589-94.
  • 53 Lyman B, Rosenberg L, Karpatkin S. Biochemical and biophysical aspects of human platelet adhesion to collagen fibers. J Clin Invest 1971; 50: 1854-63.
  • 54 Coller BS, Beer JH, Scudder LE. Adsorption of plasma glycoproteins to collagen converts platelet adhesion from being mediated by GPIa/IIa to being mediated by GPIa/IIa and/or GPIIb/IIIa. Blood 1988; 72: 318a.
  • 55 Packham MA, Evans G, Glynn MF, Mustard JF. The effect of plasma proteins on the interaction of platelets with glass surfaces. J Lab Clin Med 1969; 73: 686-97.
  • 56 Zucker MB, Vroman L. Platelet adhesion induced by fibrinogen adsorbed onto glass. Proc Soc Exp Biol Med 1969; 131: 318-20.
  • 57 Brash JL, Davidson VJ. Adsorption on glass and polyethylene from solutions of fibrinogen and albumin. Thromb Res 1976; 9: 249-59.
  • 58 Brash JL, Uniyal S. Dependence of albumin-fibrinogen simple and competitive adsorption on surface properties of biomaterials. J Polymer Sci 1979; C66: 377.